Physician profile
Robert John Fox
NPI 1427097724
$2,358.56
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2020: $28.28 · 2021: $49.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.69 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.58 | 2019 | |
| Ucb, INC. | $236.54 | 2019 | |
| Mayne Pharma Commercial LLC | $197.56 | 2019 | |
| Amgen INC. | $184.48 | 2019 | |
| Janssen Biotech, INC. | $174.81 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Genzyme Corporation | $119.63 | 2019 | |
| Pfizer INC. | $118.58 | 2019 | |
| Dermira, INC. | $112.97 | 2019 | |
| Sun Pharmaceutical Industries INC. | $79.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.16 | 2019 | |
| Leo Pharma INC. | $62.52 | 2019 | |
| Aclaris Therapeutics, INC. | $55.98 | 2019 | |
| Celgene Corporation | $51.59 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.53 | 2019 | |
| Lilly USA, LLC | $44.79 | 2019 | |
| Glenmark Therapeutics INC. | $29.00 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.25 | 2019 | |
| Epi Health, LLC | $17.36 | 2019 | |
| Almirall LLC | $15.67 | 2019 | |
| Galderma Laboratories, L.P. | $14.27 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.86 | 2019 | |
| Journey Medical Corporation | $8.70 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $4.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.